Real Time Touch



new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




Real Time Touch

Astrazeneca Ab patents


Recent patent applications related to Astrazeneca Ab. Astrazeneca Ab is listed as an Agent/Assignee. Note: Astrazeneca Ab may have other listings under different names/spellings. We're not affiliated with Astrazeneca Ab, we're just tracking patents.

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "A" | Astrazeneca Ab-related inventors


Pyrazole derivatives useful as 5-lipoxygenase activating protein (flap) inhibitors

. . . . The present application relates to novel compounds of formula (i) to their utility in treating and/or preventing clinical conditions including cardiovascular diseases (cvd), to methods for their therapeutic use, to pharmaceutical compositions containing them and to processes for preparing such compounds.. . ... Astrazeneca Ab

Compounds and their use as bace inhibitors

. . The present invention relates to compounds of formula (i) and their pharmaceutical compositions. In addition, the present invention relates to therapeutic methods for the treatment and/or prevention of aβ-related pathologies such as down's syndrome, β-amyloid angiopathy such as but not limited to cerebral amyloid angiopathy or hereditary cerebral hemorrhage, disorders associated with cognitive impairment such as but not limited to mci (“mild cognitive impairment”), alzheimer's disease, memory loss, attention deficit symptoms associated with alzheimer's disease, neurodegeneration associated with diseases such as alzheimer's disease or dementia including dementia of mixed vascular and degenerative origin, pre-senile dementia, senile dementia and dementia associated with parkinson's disease, progressive supranuclear palsy or cortical basal degeneration.. ... Astrazeneca Ab

Maleate salts of a quinazoline derivative useful as an antiangiogenic agent

The present invention relates to azd2171 maleate salt, to particular crystalline forms of azd2171 maleate salt, to processes for their preparation, to pharmaceutical compositions containing them as active ingredient, to their use in the manufacture of medicaments for use in the production of antiangiogenic and/or vascular permeability reducing effects in warm-blooded animals such as humans, and to their use in methods for the treatment of disease states associated with angiogenesis and/or increased vascular permeability.. . ... Astrazeneca Ab

2-(2,4,5-substituted-anilino)pyrimidine compounds

. . The present invention relates to certain 2-(2,4,5-substituted-anilino)pyrimidine compounds and pharmaceutically acceptable salts thereof which may be useful in the treatment or prevention of a disease or medical condition mediated through certain mutated forms of epidermal growth factor receptor (for example the l858r activating mutant, the exon19 deletion activating mutant and the t790m resistance mutant). Such compounds and salts thereof may be useful in the treatment or prevention of a number of different cancers. ... Astrazeneca Ab

Chemical compounds

. . . . . . Provided are a series of novel pyridine or pyrimidine derivatives which inhibit cdk9 and may be useful for the treatment of hyperproliferative diseases. In particular the compounds are of use in the treatment of proliferative disease such as cancer including hematological malignancies such as acute myeloid leukemia, multiple myeloma, chronic lymphocytic leukemia, diffuse large b cell lymphoma, burkitt's lymphoma, follicular lymphoma and solid tumors such as breast cancer, lung cancer, neuroblastoma and colon cancer.. ... Astrazeneca Ab

Nmda antagonist prodrugs

Prodrugs of an nmda antagonist, (s)-1-phenyl-2-(pyridin-2-yl)ethanamine, useful for the treatment of depression (particularly major depressive disorder) or pain; compositions comprising them, and methods of making them.. . ... Astrazeneca Ab

Combination comprising an omega-3 fatty acid composition and an sglt2 inhibitor

. . A method for treating nafld and/or nash and suitable compositions for carrying out the method are claimed.. . ... Astrazeneca Ab

Method of treating or prevention of atherothrombotic events in patients with history of myocardial infarction

. . The present disclosure relates to methods for reducing the rate of cardiovascular death, myocardial infarction, or stroke in a patient in recognized need thereof, comprising administering to the patient a pharmaceutical composition comprising 60 mg ticagrelor twice daily.. . ... Astrazeneca Ab

Composition for inhalation

The invention relates to a formulation comprising formoterol and budesonide for use in the treatment of respiratory diseases. The composition further contains hfa 227, pvp and peg, preferably pvp k25 and peg 1000.. ... Astrazeneca Ab

Lipid nanoparticles comprising lipophilic anti-inflammatory agents and methods of use thereof

Disclosed herein are lipid nanoparticles comprising a lipid phase and at least one lipophilic anti-inflammatory agent, and pharmaceutical compositions comprising lipid nanoparticles and methods for using lipid nanoparticles.. . ... Astrazeneca Ab

Compounds and their use as bace inhibitors

. . . . The present invention relates to compounds of formula (i) and their pharmaceutical compositions. In addition, the present invention relates to therapeutic methods for the treatment and/or prevention of aβ-related pathologies such as down's syndrome, β-amyloid angiopathy such as but not limited to cerebral amyloid angiopathy or hereditary cerebral hemorrhage, disorders associated with cognitive impairment such as but not limited to mci (“mild cognitive impairment”), alzheimer's disease, memory loss, attention deficit symptoms associated with alzheimer's disease, neurodegeneration associated with diseases such as alzheimer's disease or dementia including dementia of mixed vascular and degenerative origin, pre-senile dementia, senile dementia and dementia associated with parkinson's disease, progressive supranuclear palsy or cortical basal degeneration.. ... Astrazeneca Ab

Benzoxazinone amides as mineralocorticoid receptor modulators

. . . . . . . . Disclosed are certain derivatives of benzoxazinone amides of formula (i), or pharmaceutically acceptable salts thereof, (formula (i)) that act as mineralocorticoid (mr) receptor modulators that may reduce oxidative stress in endothelium and hence improve vascular function, to methods for their potential therapeutic use, to pharmaceutical compositions containing them and to processes for preparing such compounds.. . ... Astrazeneca Ab

[1,2,4]triazolo[4,3-b]pyridazines for use in the treatment of proliferative diseases

The invention concerns compounds of formula (i) (formula (i)) or pharmaceutically-acceptable salts thereof, wherein r1, r2 and n have any of the meanings defined herein before in the description; processes for their preparation, pharmaceutical compositions containing them and their use as anti-proliferative and/or cell-killing agents.. . ... Astrazeneca Ab

Processes for the preparation of azd5363 and novel intermediate used therein

There is provided a process for the preparation of azd5363, or a salt of azd5363, comprising: (a) the reaction of 8-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-3-oxa-1,8-diazaspiro[4.5]decane-2,4-dione: or a salt thereof, with (s)-3-amino-3-(4-chlorophenyl)propan-1-ol, or a salt thereof, in the presence of base; and (b) either isolating azd5363 or isolating azd5363 as a salt. 8-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-3-oxa-1,8-diazaspiro[4.5]decane-2,4-dione is provided and is prepared by reacting 4-(alkyloxycarbonylamino)-1-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxylic acid, or a salt thereof, with a cyclising agent. ... Astrazeneca Ab

07/13/17 / #20170198049

Methods for reducing exacerbation rates of asthma using benralizumab

. . Provided herein is are methods of reducing exacerbations of asthma in an asthma patient, comprising administering to the patient an effective amount of the anti-interleukin-5 receptor (il-5r) antibody benralizumab or an antigen-binding fragment thereof.. . ... Astrazeneca Ab

06/15/17 / #20170165248

Solid dosage form comprising proton pump inhibitor and suspension made thereof

. . . . A solid, rapidly gelling oral pharmaceutical dosage form, as well as an aqueous formulation prepared thereof, comprising a) an acid sensitive proton pump inhibitor as active ingredient distributed in a multitude of enteric coated pellets, and b) a suspension modifying granulate. Furthermore, the invention relates to an improved process for the manufacture and the use of such formulation in medical treatment, including prevention of gastrointestinal disorders in humans.. ... Astrazeneca Ab

06/08/17 / #20170157109

Nk3 receptor antagonist compound (nk3ra) for use in a method for the treatment of polycystic ovary syndrome (pcos)

A method for treating polycystic ovarian syndrome and related conditions with a compound (i): or a pharmaceutically acceptable salt thereof.. . ... Astrazeneca Ab

05/18/17 / #20170135996

Pharmaceutical depot for n-{5-[(cyclopropylamino)carbonyl]-2-methylphenyl)-3-fluoro-4-(pyridin-2-ylmethoxy)benzamide

A pharmaceutical depot comprising (i) n-{5-[(cyclopropylamino)carbonyl]-2-methylphenyl}-3-fluoro-4-(pyridin-2-ylmethoxy)benzamide, or a pharmaceutically-acceptable salt thereof, as a pharmaceutical agent (pa) and (ii) a polymer which degrades to create an acidic microclimate, wherein the pa is released from the polymer upon polymer degradation.. . ... Astrazeneca Ab

05/18/17 / #20170135981

Method for suppressing glucagon secretion of an sglt2 inhibitor

Methods are provided for avoiding an increase in glucagon secretion associated with the administration of a sodium glucose co-transporter 2 (sglt2) inhibitor via the co-administration of a dipeptidyl peptidase iv (dpp iv) inhibitor. Additionally, methods are provided for normalizing the glucagon secretion associated with the administration of a sodium glucose co-transporter 2 (sglt2) inhibitor via the co-administration of a dipeptidyl peptidase iv (dpp iv) inhibitor. ... Astrazeneca Ab

05/04/17 / #20170119759

Pharmaceutical formulation of n-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2h-pyrazol-3-yl]-4-[(3r,5s)-3,5-dimethylpiperazin-1-yl]benzamide

There are provided pharmaceutical compositions comprising a compound of formula (i) as defined herein and an amount of an alkaline effervescent agent that is sufficient to provide satisfactory in vitro dissolution; and further comprising one or more pharmaceutically acceptable ingredients; and to processes for obtaining them.. . ... Astrazeneca Ab

04/20/17 / #20170107195

Chemical compounds

. . The present invention provides a compound of a formula (i): or a pharmaceutically acceptable salt thereof; a process for preparing such a compound; and to the use of such a compound in the treatment of an enac mediated disease state (such as asthma, cf or copd).. . ... Astrazeneca Ab

02/02/17 / #20170027943

Crystalline forms of (s)-4-amino-n-(1-(4-chlorophenyl)-3-hydroxypropyl)-1-(7h-pyrrolo[2,3-d]pyrimidin-4-yl) piperidine-4-carboxamide

. . . . . . . . . . The present invention discloses certain new solid state forms of (s)-4-amino-n-(1-(4-chlorophenyl)-3-hydroxypropyl)-1-(7h-pyrrolo[2,3 -d]pyrimidin-4-yl)piperidine-4-carboxamide, processes for preparing such forms, pharmaceutical compositions comprising them, and the use of such forms in therapy.. . ... Astrazeneca Ab

01/05/17 / #20170000791

Maleate salts of a quinazoline derivative useful as an antiangiogenic agent

The present invention relates to azd2171 maleate salt, to particular crystalline forms of azd2171 maleate salt, to processes for their preparation, to pharmaceutical compositions containing them as active ingredient, to their use in the manufacture of medicaments for use in the production of antiangiogenic and/or vascular permeability reducing effects in warm-blooded animals such as humans, and to their use in methods for the treatment of disease 10 states associated with angiogenesis and/or increased vascular permeability.. . ... Astrazeneca Ab








ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Astrazeneca Ab in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Astrazeneca Ab with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###